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Abstract
Background: Reactive oxygen species and tissue remodeling regulators, such as
metalloproteinases (MMPs) and their inhibitors (TIMPs), are thought to be involved in the
development of pulmonary fibrosis. We investigated these factors in the fibrotic response to
bleomycin of p47phox -/- (KO) mice, deficient for ROS production through the NADPH-oxidase
pathway.
Methods: Mice are administered by intranasal instillation of 0.1 mg bleomycin. Either 24 h or 14
days after, mice were anesthetized and underwent either bronchoalveolar lavage (BAL) or lung
removal.
Results: BAL cells from bleomycin treated WT mice showed enhanced ROS production after PMA
stimulation, whereas no change was observed with BAL cells from p47phox -/- mice. At day 1, the
bleomycin-induced acute inflammatory response (increased neutrophil count and MMP-9 activity
in the BAL fluid) was strikingly greater in KO than wild-type (WT) mice, while IL-6 levels increased
significantly more in the latter. Hydroxyproline assays in the lung tissue 14 days after bleomycin
administration revealed the absence of collagen deposition in the lungs of the KO mice, which had
significantly lower hydroxyproline levels than the WT mice. The MMP-9/TIMP-1 ratio did not
change at day 1 after bleomycin administration in WT mice, but increased significantly in the KO
mice. By day 14, the ratio fell significantly from baseline in both strains, but more in the WT than
KO strains.
Conclusions: These results suggest that NADPH-oxidase-derived ROS are essential to the
development of pulmonary fibrosis. The absence of collagen deposition in KO mice seems to be
associated with an elevated MMP-9/TIMP-1 ratio in the lungs. This finding highlights the importance
of metalloproteinases and protease/anti-protease imbalances in pulmonary fibrosis.
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Background
Pulmonary fibrosis is a severe chronic disease with various
causes and poor prognosis. Its main histological features
include lesions of the alveolar septa, fibroblast and myofi-
broblast proliferation in lung parenchyma, abnormal
reepithelialization, and excessive extracellular matrix
macromolecule deposition [1-3]. Lung fibrosis is associ-
ated with chronic inflammation and is characterized by
the recruitment of macrophages, neutrophils, and lym-
phocytes in the airways [4]. During lung inflammation,
activated phagocytes release large amounts of reactive
oxygen species (ROS), which may be involved in tissue
injury and in impeding tissue repair, both of which lead
to pulmonary fibrosis [4-6]. Recent studies show that anti-
oxidant compounds such as N-acetylcysteine and
bilirubin protect rats against the tissue damage and pul-
monary fibrosis induced by bleomycin, an antineoplastic
antibiotic commonly used in such experimental models
[7,8]. Because these compounds can attenuate the oxidant
burden in tissue, they may prevent the lung damage
caused by ROS and subsequent fibrosis.
Metalloproteinases (MMPs) and their specific inhibitors,
the tissue inhibitors of MMPs (TIMPs), are the hallmark of
this fibrogenic microenvironment. MMPs are key
enzymes that regulate tissue remodeling through turnover
of the extracellular matrix in both normal and pathologi-
cal conditions (for review see [9]). They play a crucial role
in the fibrogenic process, as demonstrated recently
through the marked reduction of bleomycin-induced pul-
monary fibrosis in mice by batimastat, a selective MMP
inhibitor [10]. Gelatinase A (MMP-2) and gelatinase B
(MMP-9) are two MMPs that appear to be involved in pul-
monary fibrosis, but their specific roles in the process
remain unclear [9]. While MMP-9 is released primarily by
inflammatory cells, MMP-2 is synthesized by structural
cells including fibroblasts and endothelial and epithelial
cells. Both may be associated with chronic impairment of
tissue remodeling and abnormal collagen deposition [9].
Strong evidence indicates that various MMP/TIMP imbal-
ances are crucial elements in the fibrogenic process. Sev-
eral authors suggest that a "nondegrading
microenvironment" induces fibrogenicity, that is, more
specifically, that various events cause TIMP-1 levels to rise
in lung tissue, which in turn lowers MMP/TIMP ratios
[2,11,12]. Bleomycin-induced pulmonary fibrosis, for
example, causes the expression of significant levels of
TIMP-1 [13,14].
Further study is needed to illuminate the pathway that
leads from lung injury, associated with ROS and acute
inflammation, to initiation of the fibrogenic process,
which involves remodeling mediators such as MMPs and
TIMPs. The aim of the present study was to investigate the
involvement of the ROS released by inflammatory cells
during the development of pulmonary fibrosis and to
consider the consequence on MMP/TIMP balances. We
therefore examined the fibrogenic response to bleomycin
administration in mice deficient for the p47phox subunit of
NADPH-oxidase [15] and analyzed the variations in the
MMP/TIMP balance during this process.
Materials and methods
Materials
This study used the following materials, from the manu-
facturers mentioned: bleomycin sulfate from Bellon Lab-
oratories (Montrouge, France); gelatin, Triton X-100,
Coomassie Brilliant Blue, EDTA, Tween 20 solution,
hydroxyproline, and trypan blue from Sigma (St Louis,
MO, USA); May-Grünwald and Giemsa stains from RAL
(Paris, France); sodium pentobarbital from Sanofi Santé
Animale (Libourne, France); etomidate (Hypnomidate®, 2
mg/mL) from Janssen-Cilag (Issy-les-Moulineaux,
France); acrylamide, sodium dodecyl sulfate (SDS), Tris,
and BSA from Eurobio (Les Ulis, France); ELISA kits for IL-
6, TIMP-1, and pro-MMP-9 detection from R&D Systems
(Minneapolis, MN, USA); formaldehyde from Merck
(Darmstadt, Germany); isopentane from Prolabo (Fonte-
nay-sous-Bois, France); a low-range weight marker for
SDS-PAGE from Biorad (Munich, Germany); and an
ABEL® chemiluminescence kit for measurement of in vitro
ROS release from Knight Scientific Limited (Plymouth,
UK).
Bleomycin administration
Ten week-old p47phox +/+ "wild-type" (WT) and p47phox -
/- "knockout" (KO) mice (origin: LHD/NIAID/NIH,
Bethesda, MD, USA) with C57BL/6J backgrounds [15]
were housed under controlled and ethical conditions that
complied with the Interdisciplinary Principles and Guide-
lines for the Use of Animals in Research, Marketing and
Education, New York Academy of Sciences' Ad Hoc Com-
mittee on Animal Research.
Pulmonary fibrosis was induced by intranasal (i.n.) instil-
lation (under etomidate anesthesia, 15 mg i.p.) of 0.1 mg
bleomycin sulfate in saline solution (50 µL/mouse). Con-
trol mice received saline vehicle only. Either 24 h or 14
days after i.n. administration, mice were quickly anesthe-
tized by an i.p. injection of sodium pentobarbital (60 mg/
kg) and underwent either bronchoalveolar lavage (BAL)
or lung removal. These samples were stored at -80°C until
either hydroxyproline measurement or homogenization
for zymography.
Bronchoalveolar lavage and preparation of tissue 
homogenates
Mice were anesthetized with an i.p. administration (20
mL/kg) of sodium pentobarbital 0.6%. The BAL protocol
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called for washing the airways 10 times with 0.5 mL of
0.9% NaCl solution at 37°C with a 1 mL syringe. The BAL
fluid was centrifuged (600 g for 10 min, 4°C), and the
supernatant of the first two fractions (1 mL) divided into
aliquots and frozen at -80°C until analysis. The cell pellets
were then pooled with the last fractions. Total cells were
counted with a Coulter Z2® (particle counter and size dis-
tribution analyzer, Beckman Coulter). Red blood cells
were eliminated by adding 3 mL of distilled water for 30
seconds and then 1 mL of KCl 0.6 M onto the pellets. After
centrifugation (600 g for 10 min, 4°C), supernatant was
eliminated and the cells were suspended in 1 mL of PBS.
They were then cytospun at 700 rpm for 10 minutes (Cyt-
ospin 3 ®, Thermo Shandon, Ltd, Astmoor, United King-
dom) and stained with the May-Grünwald Giemsa
method. Differential cell counts of 200 cells used standard
morphological criteria.
After in vitro stimulation with phorbol 12-myristate 13-
acetate (PMA), 0.8 µM, ROS production was assayed with
a chemiluminescence technique that used the ABEL®
detection kit.
At day 14, following BAL processing, lungs were removed
and homogenized with an adapted grinder (Fast-Prep FP
120 cell disrupter, QBiogene Inc., Illkirch, France). Lung
tissue homogenates were then stored at -80°C until
analysis.
Zymographic analysis of MMPs
Since MMPs can degrade gelatin, zymographic techniques
were used to detect MMPs in both BAL (day 1 and day 14)
and lung homogenates (day 14). In nonreducing condi-
tions and in the presence of SDS, as previously described
[10], aliquots of BAL fluid or lung homogenate under-
went electrophoresis onto a 6% acrylamide stacking gel/
10% acrylamide separating gel containing 1 mg/mL gela-
tin. After electrophoresis, gels were washed twice with
2.5% Triton X-100, rinsed with water, and incubated over-
night at 37°C in 50 mM Tris, 5 mM CaCl2, 2 µM ZnCl2,
pH = 8. The gels were stained with Coomassie Brilliant
Blue in a solution of 25% ethanol-10% acetic acid in
water and rinsed in an identical solution. Gelatinase activ-
ity appeared as clear bands against blue background. We
used recombinant protein molecular weight markers (20
kDa-112 kDa) to estimate the molecular weights of the
gelatinolytic bands. Relative enzyme amounts were quan-
tified by measuring the intensity of the bands with a den-
sitometric analyzer (Bio-Profile, Vilber-Lourmat, Marne la
Vallée, France). Results were expressed as a percentage of
the band of migration of one control BAL sample loaded
onto each gel. This sample was used as an internal stand-
ard to allow further comparisons between gels.
Determination of IL-6, TIMP-1 and pro-MMP9 levels in 
BAL
The amounts of total IL-6, TIMP-1, and pro-MMP-9 were
determined with ELISA methods, performed according to
the manufacturer's recommendations. Assay sensitivity
was 31 pg/mL for TIMP-1, 15 pg/mL for IL-6, and 8 pg/mL
for pro-MMP-9.
Hydroxyproline measurement
Lung tissue was lyophilized, weighed, ground to a fine
powder with a mortar and pestle, homogenized in PBS pH
= 7.4, and divided into aliquots. After hydrolysis for 45
min in NaOH 2 N, the hydroxyproline content was
assayed in duplicate aliquots, as previously described
[16].
Expression of the results and statistical analysis
Results were expressed as means ± SEM. The differences
between the groups for treatment and strain effects were
analyzed with a nonparametric Mann-Whitney U test.
Correlations between the BAL analysis data and the MMP
levels and activity were assessed with the nonparametric
Spearman correlation test. For each analysis, P values less
than 0.05 were considered to be statistically significant.
Results
Reactive oxygen species production and cell recruitment in 
BAL fluids
At both day 1 and day 14, bleomycin treatment elicited
enhanced ROS production by BAL cells from WT mice
stimulated in vitro with PMA (Figure 1). In contrast, nei-
ther the cells removed from control mice (WT, not treated
with bleomycin) nor those from KO mice (regardless of
bleomycin treatment) could produce ROS in vitro after
PMA stimulation. No chemiluminescence was detected
when BAL cells were not stimulated by PMA in vitro.
At day 1, ROS release by BAL cells from bleomycin-treated
WT mice was accompanied by a significant neutrophil
influx, but the total BAL cell count did not rise (Table 1).
This bleomycin-induced neutrophil influx was quite
noticeable in BAL from KO mice, significantly greater than
in WT mice.
Fourteen days after bleomycin administration, the total
cell count in the WT mouse BAL increased significantly.
Specifically, the alveolar macrophage count rose mark-
edly, as did the neutrophil, eosinophil, and lymphocyte
counts, although to a lesser extent. The total cell count in
the BAL fluid of the KO mice did not increase signifi-
cantly, but the number of macrophages and lymphocytes
did. The WT mice had significantly more alveolar macro-
phages than the KO mice (Table 1).
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Production of reactive oxygen species (ROS) by bronchoalveolar lavage (BAL) cells, 1 day (A) and 14 days (B) after intranasal administrati n of bleomycin (0.1 mg, BLM) or saline (Control) to mice with the p47phox subunit of NADPH-oxidase deleted (p47phox -/- k ockout ice (KO): solid bars), compared with "Wild Type" p47phox +/+ mice (WT: blank bars)Figure 1
Production of reactive oxygen species (ROS) by bronchoalveolar lavage (BAL) cells, 1 day (A) and 14 days (B) after intranasal 
administration of bleomycin (0.1 mg, BLM) or saline (Control) to mice with the p47phox subunit of NADPH-oxidase deleted 
(p47phox -/- knockout mice (KO): solid bars), compared with "Wild Type" p47phox +/+ mice (WT: blank bars). Cells were stim-
ulated in vitro with PMA (0.8 µM) and ROS production was evaluated by chemiluminescence. Data were collected at the time of 
maximum light emission. Results are expressed as relative light units (mean ± SEM). ***: p < 0.001 comparison with control 
mice exposed to saline solution alone. ###: p < 0.001 for KO mice compared with WT mice. n = 5–9.
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Lung hydroxyproline measurement
Lung hydroxyproline concentration, which reflects colla-
gen deposition in lungs, was measured 14 days after bleo-
mycin administration to quantify pulmonary fibrosis
(Table 2). Hydroxyproline levels did not increase in the
KO mice. Moreover, although the hydroxyproline level
was similar in both strains of mice at baseline, it was sig-
nificantly higher in WT than in KO mice at day 14.
IL-6 levels in BAL fluids
IL-6 levels in the BAL fluids of WT and KO mice rose one
day after bleomycin administration (figure 2) and were
significantly higher in WT than KO mice. Fourteen days
after bleomycin administration, IL-6 levels were not sig-
nificantly different from baseline.
MMP activity in BAL fluids and lung homogenates
Zymography identified the following gelatinolytic bands
as MMP activity: pro-MMP-9 (105 kDa), MMP-9 (86
kDa), pro-MMP-2 (70 kDa), and MMP-2 (64 kDa). At day
one, pro-MMP-9 activity was significantly higher in the
BAL of bleomycin-treated KO mice than in that of their
bleomycin-treated WT counterparts, which in turn was
significantly higher than in the control mouse BAL (figure
3 and figure 4A). At day 14, no pro-MMP-9 activity was
observed in any of the mice. The active form of MMP-9
(86 kDa) was detected only in KO mouse BAL fluid at day
1 (figure 3). Pro-MMP-9 was significantly correlated with
the neutrophil count in the BAL fluids of both WT (P =
0.001) and KO (P = 7 × 10-6) mice.
At one day and 14 days after bleomycin administration,
MMP-2 activity was observed in both its latent (70 kDa)
and active (64 kDa) forms (figure 3). Although densitom-
etry analysis could detect only the 64-kD form (figure 4B)
at day one, bleomycin elicited a significant increase in the
64-kDa MMP-2 activity in both strains, compared with the
control; and this activity was substantially stronger in the
BAL of KO than WT mice. At day 14, MMP-2 activity
remained higher in both strains of bleomycin-treated
mice (compared with controls) and did not differ signifi-
cantly between them (figure 4B).
MMP activity was also evaluated at day 14 in lung
homogenates (figure 5). Homogenate from both WT and
KO mice showed similar levels of pro-MMP-9 activity lev-
els, unexpected lower than in the homogenate from the
control mice. In contrast, MMP-2 activity increased in the
lungs of WT mice only (figure 5).
Pro-MMP-9/TIMP-1 ratio in BAL fluids
We also evaluated pro-MMP-9 as well as TIMP-1 with
ELISA (table 3). The results for pro-MMP-9 confirm those
obtained with zymography. In WT mice, TIMP-1 in BAL
Table 1: Total and differential cell counts of BAL fluid from p47phox +/+ WT and p47phox -/- KO mice, at day 1 and day 14 after intranasal 
administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control, NaCl 0.9%). Results are presented as the mean (.103cells) 
± SEM. n: number of mice. WT: wild-type; KO: knockout; a: P < 0.05, b: P < 0.01, c: P < 0.001 compared with control mice exposed to 
saline solution only. *: P < 0.05, **: P < 0.01, ***: P < 0.001 for KO mice compared with WT mice.
Treatment Strain N Total Cells Macrophages Neutrophils Eosinophils Lymphocytes
Control [WT] 10 540 ± 99 536 ± 97 4 ± 2 0 0
[KO] 10 535 ± 105 393 ± 69 129 ± 37 *** 1 ± 1 11 ± 5 **
BLM, day 1 [WT] 8 490 ± 77 317 ± 50 164 ± 28 c 0 0
[KO] 9 2208 ± 733 b, e 281 ± 102 1922 ± 634 c, ** 0 2 ± 2
BLM, day 14 [WT] 8 1108 ± 80 b 991 ± 77 a 76 ± 15 c 20 ± 6 b 24 ± 13 b
[KO] 9 793 ± 118 634 ± 97 a, * 62 ± 12 18 ± 16 80 ± 33 a
Table 2: Hydroxyproline content (mg/g of dry tissue) in lung homogenate from p47phox +/+ WT and p47phox -/- KO mice, at day 14 after 
intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control, NaCl 0.9%). Results are presented as mean ± 
SEM. WT: wild-type; KO: knockout; ** : P < 0.01 for WT mice compared with KO mice. n = 3–6.
Strain Control BLM
p47phox +/+ [WT] 1.20 ± 0.26 1.74 ± 0.10**
p47phox -/- [KO] 1.29 ± 0.24 1.04 ± 0.10
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fluid was markedly higher at day one and day 14 after ble-
omycin administration than at baseline. In contrast, the
TIMP-1 level in the BAL fluid of KO mice was not signifi-
cantly modified by bleomycin administration at either
day 1 or day 14 (table 3).
Table 3 presents the calculation of the pro-MMP-9/TIMP-
1 ratio. At day one after bleomycin administration, this
ratio remained stable in the BAL of WT mice, both treated
and untreated, but rose significantly in that of the KO
mice (table 3). At day 14, the ratio was significantly lower
in both strains of treated mice than in the control mice,
and levels in the WT mice were significantly lower than
those in the KO mice.
Discussion
This study shows that mice deficient in the p47phox subu-
nit of the NADPH oxidase complex do not develop pul-
monary fibrosis after intranasal administration of
bleomycin. It also suggests that an imbalance of the molar
MMP-9/TIMP-1 ratio may influence the fibrogenic proc-
ess in this model.
Several studies previously reported that antioxidant treat-
ment attenuates the bleomycin-induced oxidative burden
and subsequent pulmonary fibrosis [7,8,17]. Moreover,
the absence of extracellular superoxide dismutase exacer-
bates conditions that lead to inflammation and
pulmonary fibrosis [18]. Although these studies suggest
that ROS contribute to lung damage and fibrosis, they do
not clearly indicate the mechanisms of the antioxidant
effect. That is, antioxidant compounds may attenuate oxi-
dative damage caused directly by bleomycin [19], or they
may limit the impact of ROS produced by phagocytes
such as macrophages and neutrophils [5] and thus inter-
fere with the inflammatory process. To clarify the role of
ROS produced by phagocytes in the development of pul-
monary fibrosis, we induced pulmonary fibrosis by i.n.
bleomycin administration to p47phox-/- KO mice. Unlike
antioxidant compounds, which nonspecifically target all
ROS sources in the tissue, knocking out the p47phox subu-
nit of the NADPH oxidase complex shuts down only the
main pathway of phagocytic ROS production. In this
study, in vitro PMA stimulation of BAL cells from KO mice
produced no detectable ROS, while BAL cells from WT
Level of IL-6 (pg/mL) in BAL fluids, 1 day after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control), to 47phox +/+ WT mice (bl nk ba s) and p47phox -/- KO mice (solid bars)Figure 2
Level of IL-6 (pg/mL) in BAL fluids, 1 day after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle 
(Control), to p47phox +/+ WT mice (blank bars) and p47phox -/- KO mice (solid bars). Results are presented as the mean ± SEM. 
** : p < 0.01 compared with control mice exposed to saline solution alone. #: p < 0.05 for p47phox -/- KO mice compared with 
p47phox +/+ WT mice. n = 4–9.
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mice did produce ROS, as previous studies of circulating
neutrophils from these mice have shown [15].
Hydroxyproline content did not increase in the lungs of
these KO mice. This finding reveals the absence of fibrosis
and thus provides strong evidence that phagocytic ROS
production is an important component of the fibrogenic
environment.
Although no ROS production was detected in KO mice,
their BAL gave evidence of an acute inflammatory
response, as did that from WT mice: bleomycin adminis-
tration elicited acute inflammation, characterized by an
influx of neutrophils and associated with increased pro-
MMP-9 activity. Moreover, the response of the KO mice to
the bleomycin resembled the abnormal "exuberant"
inflammation in vivo previously described in such KO
mice [15,20,21]. It is, however, possible that this neu-
trophil influx and the large amounts of MMP-9 it releases
have a protective effect against the development of
pulmonary fibrosis. This exaggerated inflammatory
response may be caused by defective down-regulation of
Representative gelatin zymogram of BAL supernatant fluids, 1 and 14 days after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control) to p47phox +/+ WT mice (A) and p47phox -/- KO mice (B)Figure 3
Representative gelatin zymogram of BAL supernatant fluids, 1 and 14 days after intranasal administration of bleomycin (BLM, 
0.1 mg/mouse) or saline vehicle (Control) to p47phox +/+ WT mice (A) and p47phox -/- KO mice (B). The following gelatinolytic 
bands were identified as MMP activity: pro-MMP-9 (105 kDa), MMP-9 (86 kDa), pro-MMP-2 (70 kDa), and MMP-2 (64 kDa). M: 
molecular weight marker.
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Quantification by densitometry of 105-kDa pro-MMP-9 (A), and 64-kDa MMP-2 (B) gelatinase activity on zymograms of BAL fluid, performed 1 day or 14 days after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control), to p47phox +/+ WT mice (blank bars) and p47phox -/- KO mice (s lid bars)Figure 4
Quantification by densitometry of 105-kDa pro-MMP-9 (A), and 64-kDa MMP-2 (B) gelatinase activity on zymograms of BAL 
fluid, performed 1 day or 14 days after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control), 
to p47phox +/+ WT mice (blank bars) and p47phox -/- KO mice (solid bars). Results are represented as the mean of relative 
intensity ± SEM. * : p < 0.05, ** : p < 0.01, *** : p < 0.001 compared with control mice exposed to saline solution alone. ###: p 
< 0.001 for p47phox -/- KO mice compared with p47phox +/+ WT mice. n = 8–10.
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Quantification by densitometry of Pro-MMP-9 (105 kDa, A) and MMP-2 (64 kDa, B) gelatinase activity on zymograms of lung homogen es, performed 14 days after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control) t  p47phox -/- KO mice (solid bars) and p47phox +/+ WT mice (blank bars)Figure 5
Quantification by densitometry of Pro-MMP-9 (105 kDa, A) and MMP-2 (64 kDa, B) gelatinase activity on zymograms of lung 
homogenates, performed 14 days after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle (Control) 
to p47phox -/- KO mice (solid bars) and p47phox +/+ WT mice (blank bars). Results are represented as the mean of relative 
intensity ± SEM. * : p < 0.05, ** : p < 0.01, compared with control mice exposed to saline solution alone. ##: p < 0.01 for 
p47phox -/- [KO] mice compared with p47phox +/+ WT mice. n = 3–5.
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the inflammatory process in these KO mice, perhaps due
to the absence of ROS and the failure to degrade chemo-
tactic signals [22].
This acute inflammation was accompanied by signifi-
cantly elevated IL-6 levels in the BAL fluids of both strains
of mice on the day after bleomycin administration, levels
significantly higher in WT than KO mice. Given that IL-6
is secreted primarily by mononuclear cells, specifically
macrophages, the difference between strains suggests that
these cells are activated more weakly in the KO than in the
WT mice. Moreover, in SP-D -/- alveolar macrophages, the
NADPH oxidase inhibitor apocynin inactivates NF-kappa
B, the transcription factor that regulates numerous proin-
flammatory responses, including IL-6 release [23]. Simi-
larly, lipopolysaccharide-induced NF-kappa B activation
is impaired in nuclear protein extracts of lung tissue from
p47phox-/- KO mice [24]. This would explain why IL-6
response seems to be redox-sensitive in our experiment.
MMP induction, assessed by gelatinase release, has been
reported in various cases of pulmonary fibrosis in human
and experimental models [13,25,26]. We therefore ana-
lyzed the gelatinolytic activities of MMPs, in both BAL
fluid and lung homogenate. MMP-9 and MMP-2 activities
in the BAL fluid of the KO mice reveal an intense response
to bleomycin. MMP-9 levels were highly correlated with
neutrophil infiltration, while MMP-2 is known to be pro-
duced mainly by epithelial [27] and mesenchymal cells,
such as fibroblasts, which are involved in collagen pro-
duction and deposition [9,25]. This suggests that the exag-
gerated response observed in the BAL fluid of KO mice
involves a wide spectrum of cell types. Surprisingly, at day
14, gelatinase profiles were different in the lung homoge-
nates than in BAL fluids. Although MMP-2 activity was
equivalent in BAL of both strains, MMP-2 activity
increased substantially in the lung homogenate of the WT
mice. One possible explanation is that the increased
release of MMP-2 in the inner lung parenchyma may
result from downstream events caused by phagocyte acti-
vation and ROS production during inflammation. This is
consistent with another study, mentioned above, in
which apocynin, an inhibitor of NADPH oxidase, also
inhibited the release of MMP-9 and MMP-2 in SP-D -/-
alveolar macrophages [23]. Moreover, Pardo et al. [28]
report increased levels of gelatinases (MMP-2 and MMP-
9) in isolated type II alveolar cells from hyperoxic rats;
these increases are associated with alterations in the bal-
ance between MMPs and TIMPs and finally lead to diffuse
alveolitis and its progression to pulmonary fibrosis.
It is thus difficult to reach a definitive conclusion at this
time about the exact function of MMPs. They play a role
in promoting tissue remodeling and counterbalancing
excessive matrix deposition, but may also facilitate tissue
damage and disruption. Their involvement in bleomycin-
induced pulmonary fibrosis has been demonstrated with
the inhibition of collagen deposition by bastimastat, a
nonselective MMP-inhibitor [10]. Complete understand-
ing of the dynamic process of remodeling nonetheless
requires consideration of TIMPs, which are natural MMP
inhibitors.
Increased TIMP-1 expression has been observed in lung
extracts and in BAL fluids after bleomycin administration
and after the transfer of the active TGF-beta gene to "fibro-
sis-prone" C57BL/6 mice [11,14]. In humans, increased
levels of TIMP protein and RNA are observed in lungs of
patients with idiopathic pulmonary fibrosis, and TIMP
expression there exceeds that of MMP [12]. A reduced
molar MMP/TIMP ratio seems to be a hallmark of pulmo-
nary fibrosis, distinguishing it from other reversible inter-
Table 3: Levels of pro-MMP-9 and TIMP-1, and pro-MMP-9 / TIMP-1 ratio in BAL supernatant fluids, recovered from p47phox +/+ [WT] 
and p47phox -/- [KO] mice, 1 day or 14 days after intranasal administration of bleomycin (BLM, 0.1 mg/mouse) or saline vehicle 
(Control, NaCl 0.9%). For Pro-MMP-9 and TIMP-1, results are represented as the mean (pg/ml) ± SEM. N : number of mice. a : P < 
0.05, b : P < 0.01, in comparison to control mice exposed to saline solution only. * : P < 0.05, ** : P < 0.01, for [KO] mice in comparison 
to [WT] mice.
Treatment Strain N Pro-MMP-9 TIMP-1 Ratio Pro-MMP-9 / 
TIMP-1
Control [WT] 5 46.3 ± 14.9 38.7 ± 13.5 2.7 ± 1.3
[KO] 5 1314.7 ± 798.2 ** 325.2 ± 173.6 10.4 ± 4.7
BLM, day 1 [WT] 7 2645.9 ± 1 011.6 b 781.8 ± 158.9 b 3.8 ± 1.3
[KO] 8 23646.8 ± 2 359.7 b, ** 1 213.8 ± 396.4 60.8 ± 23.7 a, **
BLM, day 14 [WT] 7 37.7 ± 9.1 2693.3 ± 378.3 b 0.02 ± 0.00 b
[KO] 6 137.9 ± 15.5 b 567.9 ± 163.5** 0.2 ± 0.1 b, **
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stitial lung diseases [26] and from chronic obstructive
pulmonary disease (COPD) [29]. This ratio might be con-
sidered to be a "snapshot" of the dynamic matrix remod-
eling in lung tissue.
Interestingly, in our study, the pro-MMP-9/TIMP-1 ratio
was significantly higher for KO than WT mice, at both day
one and day 14. At day 1 this was due to the lower MMP-
9 level and higher TIMP-1 level in the BAL from WT mice,
and at day 14, only to the latter. The correlation of these
levels with differences in hydroxyproline levels in the
lungs of bleomycin-treated mice strongly suggests that a
reduced molar pro-MMP-9/TIMP-1 ratio in BAL fluid is
associated with collagen deposition, beginning as early as
the inflammatory events at day 1 after bleomycin
administration.
The usefulness of the pro-MMP-9/TIMP-1 ratio as a
marker of fibrosis nonetheless requires discussion.
Although a molar ratio appears to play a protective role
against fibrotic changes, MMP-9 is considered primarily to
be an inflammatory mediator released by leukocytes dur-
ing acute inflammatory events to facilitate their progres-
sion across the basement membrane [30]. Moreover,
MMP-9 depletion in KO mice does not substantially alter
the extent of either pulmonary fibrosis or lung inflamma-
tion after bleomycin administration [31]. TIMPs may also
counterbalance the activity of MMP-2 or other protein-
ases, such as collagenases. Ruiz et al. [32] recently
observed that MMP-8 and MMP-13 RNA levels decreased
and TIMP-1 RNA increased in the paraquat- and hyper-
oxia-induced pulmonary fibrosis rat model. Matrilysin
(MMP-7), which can degrade various substrates, seems to
have a crucial role in pulmonary fibrosis [33]. Finally, the
exuberant neutrophil influx observed at day one in
p47phox-/- KO mice could provide great amount of other
kind of protease, such as serine proteases. Indeed, neu-
trophil elastase was shown to have an impact on the sever-
ity of bleomycin-induced pulmonary fibrosis [34,35]
Conclusion
In summary, this study demonstrates that the inability of
phagocytes from p47phox-/- KO mice to produce large
quantities of ROS via the NADPH oxidase pathway inhib-
its the development of bleomycin-induced pulmonary
fibrosis. This inhibition is associated with changes in IL-6
production and in the molar MMP-9/TIMP-1 ratio, both
probably key factors in airway remodeling and fibrosis.
These rapidity of these differences after bleomycin admin-
istration suggests that early inflammatory events and
remodeling events may establish a favorable environment
for further chronic fibrogenic processes.
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